Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 15(4): e37355, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37182048

ABSTRACT

Cholecystic parastomal herniation is a rare condition that has only been documented 16 times in the literature. We present a case report and literature review of cholecystic parastomal herniation managed with diagnostic laparoscopy without cholecystectomy or hernia repair. Furthermore, we assess the demographics, presentation, stoma types, and management of cholecystic parastomal hernias across all documented cases.

2.
Blood ; 118(23): 6132-40, 2011 Dec 01.
Article in English | MEDLINE | ID: mdl-22001392

ABSTRACT

We previously demonstrated that the gene encoding PTPROt, the truncated form of protein tyrosine phosphatase receptor type O expressed predominantly in hematopoietic cells, is a candidate tumor suppressor and is down-regulated in chronic lymphocytic leukemia (CLL). Here, we show that PTPROt expression is significantly reduced in CD19(+) spleen B cells from Eµ-T cell leukemia 1 (TCL1) transgenic mice relative to the wild-type mice. Strikingly, as much as a 60% decrease in PTPROt expression occurs at 7 weeks independently of promoter methylation. To elucidate the potential mechanism for this early suppression of PTPROt in these mice, we explored the role of activating protein-1 (AP-1) in its expression. We first demonstrate that AP-1 activation by 12-O-tetradecanoylphorbol-13-acetate induces PTPROt expression with concurrent recruitment of c-fos and c-jun to its promoter. The PTPROt promoter is also responsive to over- and underexpression of AP-1, confirming the role of AP-1 in PTPROt expression. Next, we demonstrate that TCL1 can repress the PTPROt promoter by altering c-fos expression and c-jun activation state. Finally, using primary CLL cells we have shown an inverse relationship between TCL1 and PTPROt expression. These findings further substantiate the role of TCL1 in PTPROt suppression and its importance in the pathogenesis of CLL.


Subject(s)
Gene Expression Regulation, Leukemic/physiology , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Proto-Oncogene Proteins/metabolism , Receptor-Like Protein Tyrosine Phosphatases, Class 3/genetics , Transcription Factor AP-1/metabolism , Animals , Disease Models, Animal , Down-Regulation/genetics , Humans , K562 Cells , Leukemia, B-Cell/genetics , Leukemia, B-Cell/metabolism , Leukemia, B-Cell/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Mice , Mice, Inbred C3H , Mice, Transgenic , Phosphorylation/physiology , Promoter Regions, Genetic/genetics , Proto-Oncogene Proteins c-fos/metabolism , Proto-Oncogene Proteins c-jun/metabolism , U937 Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...